Magnesium 3-(tert-butoxy)-3-oxopropanoate | 80297-45-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Magnesium 3-(tert-butoxy)-3-oxopropanoate
• 英文别名: magnesium;3-[(2-methylpropan-2-yl)oxy]-3-oxopropanoate
• CAS: 80297-45-6
• 化学式: C₁₄H₂₂MgO₈
• 分子量: 342.629
• InChiKey: GRBMOFAYJFJXCG-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -1.44
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  133
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Magnesium 3-(tert-butoxy)-3-oxopropanoate 在 N,N'-羰基二咪唑 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 19.33h， 生成 tert-butyl (2S,6S)-6-methyl-2-(1-methyltriazol-4-yl)-4-oxopiperidine-3-carboxylate
  参考文献：
  名称：

  WO2023/28237

  摘要：

  公开号：
• 作为产物：
  描述：

  丙二酸单叔丁酯 、 magnesium ethylate 以 四氢呋喃 为溶剂， 以89.8 %的产率得到Magnesium 3-(tert-butoxy)-3-oxopropanoate
  参考文献：
  名称：

  WO2023/28237

  摘要：

  公开号：

文献信息

• STING AGONIST COMPOUNDS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20190300513A1

  公开（公告）日：2019-10-03

  Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

  提供具有一般公式(I)、一般公式(II)、一般公式(III)、一般公式(IV)、一般公式(V)、一般公式(VI)及其药用可接受盐的化合物，其中所有变量均在此定义，这些化合物可能作为I型干扰素产生的诱导剂，特别是作为STING活性剂。还提供包含这些化合物的组合物、合成这些化合物的过程以及这些化合物的用途，包括将这些化合物用于诱导免疫反应、诱导STING依赖的I型干扰素产生和/或治疗细胞增殖紊乱，如癌症。
• [EN] SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF<br/>[FR] ACIDES PYRIDYL-CYCLOALKYL-CARBOXYLIQUES SUBSTITUÉS, COMPOSITIONS LES CONTENANT ET LEURS UTILISATIONS MÉDICALES
  申请人：BAYER PHARMA AG

  公开号：WO2016097013A1

  公开（公告）日：2016-06-23

  The present invention relates to substituted Pyridyl-cycloalkyl- carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis.

  本发明涉及一般式(I)的取代吡啶基-环烷基-羧酸，涉及包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是在哺乳动物中，如与疼痛相关的疾病，或用于治疗或预防疼痛综合症（急性和慢性）、炎症诱导的疼痛、盆腔疼痛、癌症相关的疼痛、子宫内膜异位症相关的疼痛以及子宫内膜异位症和子宫腺肌症本身、癌症本身以及增生性疾病本身，如子宫内膜异位症。
• 2,4-Dihydroxyadipic acid derivative
  申请人：Kanegafuchi Chemical Industry Co., Ltd.

  公开号：EP0464817A1

  公开（公告）日：1992-01-08

  A novel 2,4-dihydroxyadipic acid derivative of the formula: wherein R¹ and R⁴ are the same or different and each a hydrogen atom, an alkyl group, an aralkyl group, an aryl group or a silyl group, and R² and R³ are the same or different and each a hydrogen atom or a protective group of a hydroxy group or together form a ring, which is useful as a common intermediate in the synthesis of HMG-CoA reductase inhibitor.

  一种新颖的 2,4-二羟基己二酸衍生物，其化学式为 其中 R¹ 和 R⁴ 相同或不同，各为氢原子、烷基、芳烷基、芳基或硅烷基，R² 和 R³ 相同或不同，各为氢原子或羟基的保护基团或共同形成一个环，可用作合成 HMG-CoA 还原酶抑制剂的普通中间体。
• Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10172814B2

  公开（公告）日：2019-01-08

  The present invention relates to substituted Pyridyl-cycloalkyl-carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis.

  本发明涉及通式（I）的取代吡啶基-环烷基-羧酸、包含上述化合物的药物组合物和组合物，以及使用上述化合物制造药物组合物，用于治疗或预防疾病，尤其是哺乳动物的疾病、如与疼痛相关的疾病，或用于治疗或预防疼痛综合征（急性和慢性）、炎症引起的疼痛、盆腔疼痛、癌症相关疼痛、子宫内膜异位症相关疼痛以及子宫内膜异位症和子宫腺肌症、癌症以及子宫内膜异位症等增殖性疾病。
• Sting agonist compounds
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10793557B2

  公开（公告）日：2020-10-06

  Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

  本发明提供了通式(I)、通式(II)、通式(III)、通式(IV)、通式(V)、通式(VI)的化合物及其药学上可接受的盐类，其中所有变量均在本文中定义，这些化合物可用作I型干扰素产生的诱导剂，特别是作为STING活性剂。此外，还提供了包含此类化合物的组合物、合成此类化合物的工艺以及此类化合物的用途，包括施用此类化合物诱导免疫反应、诱导 STING 依赖性 I 型干扰素产生和/或治疗细胞增殖障碍，如癌症。